Zhizhuang Zhao to Janus Kinase 2
This is a "connection" page, showing publications Zhizhuang Zhao has written about Janus Kinase 2.
Connection Strength
5.709
-
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS One. 2020; 15(6):e0232801.
Score: 0.698
-
Specific dephosphorylation of Janus Kinase 2 by protein tyrosine phosphatases. Proteomics. 2015 Jan; 15(1):68-76.
Score: 0.478
-
Generation and characterization of a JAK2V617F-containing erythroleukemia cell line. PLoS One. 2014; 9(7):e99017.
Score: 0.465
-
Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. J Immunol. 2014 Jul 15; 193(2):477-84.
Score: 0.462
-
Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. J Hematol Oncol. 2014 Mar 19; 7:25.
Score: 0.454
-
Development of a highly sensitive method for detection of JAK2V617F. J Hematol Oncol. 2011 Oct 10; 4:40.
Score: 0.384
-
Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory. J Hematol Oncol. 2011 Jan 14; 4:4.
Score: 0.365
-
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008 May 15; 111(10):5109-17.
Score: 0.299
-
Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity. Exp Hematol. 2007 Nov; 35(11):1624-32.
Score: 0.288
-
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2007 Feb 09; 282(6):3428-32.
Score: 0.275
-
JAK2(V617F): Prevalence in a large Chinese hospital population. Blood. 2007 Jan 01; 109(1):339-42.
Score: 0.269
-
ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis. Leukemia. 2019 05; 33(5):1287-1291.
Score: 0.159
-
Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight. 2017 04 06; 2(7):e90932.
Score: 0.140
-
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera. Ann Hematol. 2015 Apr; 94(4):717-9.
Score: 0.119
-
Stem and progenitor cell subsets are affected by JAK2 signaling and can be monitored by flow cytometry. PLoS One. 2014; 9(4):e93643.
Score: 0.114
-
Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6091-6.
Score: 0.106
-
The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis. Am J Pathol. 2012 Sep; 181(3):858-65.
Score: 0.101
-
Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: significance of the para-hydroxyl orientation. Bioorg Med Chem Lett. 2012 Feb 01; 22(3):1402-7.
Score: 0.097
-
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia. 2011 Nov; 13(11):1058-68.
Score: 0.096
-
A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth. Exp Hematol. 2012 Jan; 40(1):22-34.
Score: 0.096
-
Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark. 2007; 3(6):315-24.
Score: 0.069
-
Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol. 2005 Oct; 42(4):221-9.
Score: 0.063
-
Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005 Jun 17; 280(24):22788-92.
Score: 0.061
-
HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression. Blood. 2022 05 05; 139(18):2797-2815.
Score: 0.050